Triphase Accelerator Corporation

facit.ca
Innovation Type:
Therapeutics
Cancer Type:
Multiple
Funding Stage:
Series A,B,C
Fund:
Compass Rose
Triphase Accelerator is dedicated to advancing novel compounds from pre-IND through Phase 2 clinical proof-of-concept studies using a unique, science-based model that is faster and more cost-effective than traditional pharmaceutical industry approaches.

Related news

FACIT Features: Triphase Accelerator initiates Phase 1 clinical trial of next-gen ADC for B-cell lymphoma

April 1, 2019 – Triphase Accelerator has dosed their first patient in a Phase 1 clinical trial of TRPH-222, an anti-CD22 antibody-drug conjugate (ADC) for the treatment of patients with lymphoma. Read More

Triphase Accelerator Announces Acquisition of its First Compound, Marizomib, by Celgene Corporation

Triphase Accelerator Announces that Celgene Corporation has acquired the company's assets related to its proteasome inhibitor, marizomib, which is in development for glioblastoma and relapsed and/or refractory multiple myeloma. Read More

Triphase Accelerator Announces New Product Option Deal with Celgene

Triphase Accelerator Corporation announced a new strategic collaboration with Celgene Corporation, that provides Celgene with an option to acquire all Triphase Accelerator’s assets relating to TRPH 222 (CD22-4AP), an antibody-drug conjugate in development for lymphoma. Read More

Triphase Accelerator Corporation Announces FDA Orphan Drug Designation for Marizomib in Malignant Glioma

Triphase is evaluating marizomib in combination with bevacizumab in patients with recurrent glioblastoma. Read More

Triphase Signs Collaboration and Option Agreement with Celgene Corporation

Triphase was spun out of the Ontario Institute for Cancer Research to develop and advance late pre-clinical, Phase I or early Phase II potential products. Read More

Catalent Biologics and Triphase Accelerator Corporation Announce License Agreement to Advance SMARTag™ ADC to Clinic

Triphase will obtain worldwide rights to further develop Catalent's proprietary CD22-4AP Antibody-Drug Conjugate (ADC), which has been developed by Catalent’s wholly owned subsidiary, Redwood Bioscience, Inc., using its SMARTag™ technology platform. Read More

    CONNECT WITH FACIT

    Learn more about how we are driving made-in-Ontario oncology innovations reach the market.